RxDoctor Payments Data

David Shu, MD

Internal Medicine · San Francisco, CANPI 1285675355

Payments from drug & device makers

$3,314in general payments, 2019–2025

Across 107 payments — averaging $30.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$336
  • GSK$330
  • Lilly USA, LLC$210
  • Astellas Pharma US Inc$164
  • Johnson & Johnson$125
  • plus $666 from 11 others

What the payments were for

  • Food & beverage$3,314100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,314 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$50,079
Medicare patients
154
Services billed
679

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin105$135,006
EliquisApixaban28$33,766
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$23,211
Breztri AerosphereBudesonide/Glycopyr/Formoterol32$19,493
VemlidyTenofovir Alafenamide11$15,352
DuleraMometasone/Formoterol17$8,052
XareltoRivaroxaban13$7,107
Atorvastatin Calcium494$5,203
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$4,640
Rosuvastatin Calcium95$4,035
Febuxostat14$3,431
Wixela InhubFluticasone Propion/Salmeterol17$2,486
Metformin Hcl ErMetformin Hcl141$2,436
Levothyroxine Sodium173$2,344
Losartan Potassium208$1,920

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$55$135,006105 claims
PfizerEliquis$96$33,76628 claims
GSKTrelegy Ellipta$330$23,21137 claims
AstraZenecaBreztri Aerosphere$1,483$19,49332 claims
GileadVemlidy$112$15,35211 claims
Johnson & JohnsonXarelto$125$7,10713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →